Easy Six Vaccine

Quick links

Choose a section

Quick links to important sections

Advertisements

Easy Six Vaccine

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Easy Six Vaccine

What is Easy Six Vaccine? (DTaP-IPV-Hib-HepB)

Property Description
Active Ingredients Diphtheria Toxoid, Tetanus Toxoid, Acellular Pertussis Vaccine, Inactivated Poliovirus Vaccine, Hib Conjugate, Hepatitis B (rDNA) Vaccine
Form Suspension for injection
Pharmacological Class Active Immunizing Agent; Combination Vaccine
Common Use Prevention (Prophylaxis) of six major infectious diseases
Origin Biological product (derived from bacterial, viral, and recombinant components)

What is the Easy Six Vaccine and How is it Classified?

The Easy Six Vaccine is a commercially recognized, single-injection preparation classified as a hexavalent combination vaccine, belonging to the high-level pharmacological class of Active Immunizing Agents. This biological product is engineered to provide simultaneous protection against six distinct, severe infectious diseases: Diphtheria, Tetanus, Pertussis (Whooping Cough), Poliomyelitis (Polio), Hepatitis B, and invasive disease caused by Haemophilus influenzae type b (Hib). This comprehensive combination is widely recognized in pediatric medicine for its efficacy in providing broad protection.

What is the Easy Six Vaccine Composed Of?

This vaccine is composed of six distinct active components, or antigens, presented as a sterile Suspension for injection. The key active ingredients include Toxoids (inactivated toxins) for Diphtheria and Tetanus, purified bacterial proteins for the Acellular Pertussis component, three types of the Inactivated Poliovirus Vaccine, the Hib Conjugate Vaccine, and the Recombinant Hepatitis B surface antigen. These components are formulated with an adjuvant, typically an aluminum salt, which is clinically confirmed to enhance and prolong the body's immune response to these multiple antigens.

What is the General Purpose of This Multicomponent Vaccine?

The general purpose of the Easy Six Vaccine is primary prophylaxis, or the prevention of the six targeted diseases, by inducing active immunity in the recipient. The combination design is particularly useful in pediatric care, as it streamlines the complex immunization schedule required for infants and toddlers. This single-shot efficiency ensures that the patient receives complete and timely protective coverage against a range of serious childhood illnesses.

Regulatory References

  1. Active Immunization Agents (NIH, MedlinePlus)
  2. EPAR for Infanrix Hexa (DTaP-IPV-Hib-HepB)
Advertisements

What side effects are possible with Easy Six Vaccine?

Possible side effects and safety information

The official safety profile for the Easy Six Vaccine (DTaP-IPV-Hib-HepB) classifies adverse reactions based on their frequency and the physiological system affected, as documented in regulatory sources such as the EMA and FDA.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped into categories based on occurrence in clinical trials:

  • Very Common (Affecting 1 in 10): These frequently observed, typically transient reactions include irritability, somnolence (drowsiness), decreased appetite, fever (38.0 C), and local reactions such as pain, swelling, and redness at the injection site. Local symptoms generally resolve within 48 hours.
  • Common (Affecting 1 in 100): Vomiting and diarrhea are classified within this group.
  • Incidence Not Known (Post-Marketing): Rare reports exist for serious events such as Guillain-Barré syndrome and anaphylaxis (severe allergic reaction).

Reactions are also categorized by the System-Organ Class (SOC) involved, including General Disorders (fever), Nervous System Disorders (somnolence, convulsions), and Gastrointestinal Disorders (vomiting).

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight specific, serious reactions and constraints:

  • Serious Adverse Reactions: The label documents rare but clinically significant events, including Hypotonic-Hyporesponsive Episode (HHE), which is a collapse or shock-like state occurring within 48 hours, and Convulsions/Seizures, occurring within three days.
  • Population-Specific Notes: The potential risk of apnoea (temporary cessation of breathing) requires safety consideration for very premature infants (born leq 28 weeks of gestation), with respiratory monitoring sometimes considered for 48–72 hours.
  • Safety Restrictions: A confirmed history of anaphylaxis to a previous dose or any component, or the presence of a progressive or uncontrolled neurological disorder, constitutes a safety restriction outlined in the regulatory prescribing information.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This section details official regulatory information regarding overdose for the Easy Six Vaccine.

Overdose Status and Context

Official labeling indicates that the chances of an overdose with the Easy Six Vaccine are unlikely. This determination is based on the method of administration, as the vaccine is administered by a healthcare professional under medical supervision in a controlled clinical setting. Due to this procedural safeguard, regulatory documents do not provide a detailed profile of clinical symptoms or specific emergency management steps for an overdose event.

Official Regulatory Statements

Regulatory sources explicitly state the following about an overdose with this vaccine:

Overdose Component Official Regulatory Status
Overdose Likelihood Stated as unlikely
Context Constraint Administration is conducted under medical supervision

Emergency Action

Because the vaccine is given in a supervised medical setting, the primary focus of the regulatory profile is on prevention rather than post-event management. Should any unexpected or severe reactions occur following administration, the supervising healthcare professional should be notified immediately for necessary evaluation and supportive care, as is standard procedure for any administered medicinal product.

Advertisements

Therapeutic Uses of Easy Six Vaccine

Protection Against Six Major Infectious Diseases

This vaccine is commonly used to help protect against six serious infectious diseases in infants and toddlers. It addresses conditions characterized by periods of heightened symptoms related to Diphtheria, Tetanus (lockjaw), Pertussis (whooping cough), Poliomyelitis (Polio), Hepatitis B, and invasive diseases caused by Haemophilus influenzae type b (Hib). It is applied in the foundational stages of the immunization schedule to support the development of immunity against these dangerous infections, which is considered relevant for easing the risk of these conditions.


Managing the Risk of Serious Symptom Clusters and Complications

The use of this medication plays a role in managing the risk of severe symptoms that can lead to critical illness, such as life-threatening spasms, paralysis, and severe respiratory distress. By addressing the risk of these pronounced manifestations, the vaccine may assist with maintaining functional stability by reducing the risk of long-term disability and supports general well-being during symptomatic phases.


Simplified Immunization for Greater Comfort and Compliance

This is a combination vaccine, meaning it is applied in addressing the burden of multiple separate administrations. This contributes to improved comfort during periods of heightened symptoms (related to the process itself) and is commonly used to support timely administration, which is relevant for easing the process of achieving protection.

Quick Fact: Relevant for Managing Process Discomfort

The combined nature may assist with maintaining functional stability by managing symptoms that interfere with daily functioning during the administration phase.

Regulatory References

  1. European Medicines Agency (EMA) overview
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Easy Six Vaccine?

The Easy Six Vaccine is officially indicated for the pediatric population only, specifically infants and young children for primary immunization, starting at six weeks of age. The vaccine is not indicated for use in adolescents, adults, or older children, with the maximum approved age typically set at the fifth or seventh birthday, depending on the regulatory document.

Absolute Contraindications

Use is contraindicated and must not occur in individuals with a history of a severe allergic reaction (anaphylaxis) to a prior dose of this vaccine or any of its components, including residuals such as neomycin or formaldehyde. It is also prohibited if the infant experienced encephalopathy of unknown etiology within seven days following a previous pertussis-containing vaccine dose.

Conditional Restrictions

Administration must be postponed for children experiencing a moderate or severe acute febrile illness. Additionally, the vaccination of very premature infants (born at or before 28 weeks' gestation) requires special caution, as the potential risk of apnoea necessitates respiratory monitoring for 48 to 72 hours, as noted in regulatory guidelines.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of the Easy Six Vaccine (DTaP-IPV-Hib-HepB) primarily through effects on the expected immune response and mandatory administration requirements.

Documented Immunological Interference

Co-administration of immunosuppressive therapies (including high-dose corticosteroids, chemotherapy, and irradiation) may officially reduce the expected immune response to the vaccine, potentially lowering its protective efficacy. This consideration is specifically noted in labels for immunosuppressed patients, including those with chronic conditions such as HIV infection, where the expected immunological response may not be fully obtained.

Administration and Procedural Restrictions

Interaction Type Restriction/Requirement
Physical Incompatibility The vaccine must not be mixed in the vial or syringe with any other vaccine or parenteral medicinal product.
Timing/Site Rule Simultaneous administration of other injectable vaccines (such as Tetanus Immune Globulin or other required vaccines) must be performed at separate injection sites (preferably different limbs).
Co-administration Effect Simultaneous administration with certain vaccines, such as the Pneumococcal Conjugate Vaccine, is officially associated with a higher rate of fever (reactogenicity).

Diagnostic Interference

The official labeling notes a temporary diagnostic interference: a false positive urine test for Haemophilus influenzae type b can be observed for at least 30 days following vaccination due to transient antigen excretion.

Advertisements

Mechanism of Action

The Easy Six Vaccine is a hexavalent combination of purified antigens and toxoids designed to modulate the adaptive immune system. Its mechanism involves the administration of six distinct immunogenic components: Diphtheria and Tetanus toxoids, acellular Pertussis components, Inactivated Poliovirus strains (Types 1, 2, and 3), Recombinant Hepatitis B surface antigen (HBsAg), and the Haemophilus influenzae type b (Hib) polyribosylribitol phosphate (PRP) polysaccharide conjugated to a carrier protein.

Upon intramuscular delivery, the antigens are processed by antigen-presenting cells (APCs), such as dendritic cells, which subsequently present the epitopes to T-cells. The diphtheria and tetanus toxoids, which are chemically detoxified, induce the generation of neutralizing antibodies specific to the toxins. The whole-cell Bordetella pertussis component initiates a humoral and cellular response against bacterial structures. The inactivated polio viral particles stimulate the production of corresponding anti-poliovirus antibodies. The recombinant HBsAg promotes anti-HBs antibody generation, while the Hib conjugate component facilitates T-cell dependent B-cell activation, yielding anti-PRP antibodies. This cascade establishes a sustained immunological memory against the six represented pathogens.

Advertisements

Dosage and Administration Information

Official Instructions for Administration and Schedule

The Easy Six Vaccine is a hexavalent combination vaccine whose use is strictly governed by national and intergovernmental standards. It is intended for the infant and toddler population, with the first dose recommended as early as six weeks of age.

Dosage and Route

Instruction Detail
Dose Volume A fixed volume of 0.5 mL per injection for both the primary series and any subsequent booster dose.
Administration Route Must be given exclusively by Intramuscular (IM) injection. It is strictly forbidden to administer it intravenously.
Injection Site The preferred site for infants younger than one year of age is the anterolateral aspect of the thigh.

Vaccination Schedule and Timing

The full course of administration consists of a primary series followed by a booster dose:

  • Primary Series: This generally involves two or three doses, with a minimum interval of at least one month between doses.
  • Booster Dose: A booster must be given at least six months after the last dose of the primary series, typically during the second year of life.

Preparation Requirements

Before administration, the vaccine suspension should be shaken gently to ensure it is uniform (cloudy, white to off-white). It must also be visually inspected for any foreign particles or discoloration. The vaccine must not be frozen and should not be mixed with any other vaccines or medicinal products in the same syringe.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Easy Six Vaccine

Evidence for Protection Against Six Major Diseases

Research explored the immune responses associated with the Easy Six Vaccine in the context of six target conditions: Diphtheria, Tetanus, Pertussis (Whooping Cough), Poliomyelitis, Hepatitis B, and invasive disease caused by Haemophilus influenzae type b (Hib). The main body of research consists of large-scale Randomized Controlled Trials (RCTs) and Comparative Phase 3 Trials. These studies were designed to measure the immune response across all six components.

Researchers primarily used Immunogenicity as a measure of outcomes, examining the production of specific antibodies. Comparative trials documented that the immune responses observed with the combined vaccine, when measured by antibody levels, were comparable to those of the reference vaccines, according to pre-defined study criteria. Findings contribute to understanding the observed immune responses.

Long-term Follow-up and Durability of Response

A key focus of the research has been exploring how long the observed immune response persisted in the study populations. Studies monitored the immune response following the administration of a booster dose, typically given in the second year of life. Studies explored the persistence of antibody levels over defined time intervals, with data showing patterns related to levels observed up to the preschool age.

However, existing studies provide limited insight into how long the antibodies against all six components will remain at measured levels well beyond the preschool years. Long-term effects are not fully established, and research is ongoing to better characterize the persistence of the immune response.

Evidence Gaps and Areas of Scientific Uncertainty

The research framework relies on extensive comparative data, but it is important to note the specific scientific measures used. The evidence often uses Immunogenicity (antibody production) as a surrogate endpoint. This means that researchers measure the immune system's reaction rather than directly tracking the prevention of clinical disease in every trial. Furthermore, subgroup findings are uncertain for specific, complex patient groups. Findings describe group patterns, not personal outcomes, and evidence is still emerging in these areas.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Easy Six Vaccine (FAQ)


Q: Is Easy Six Vaccine considered a standard or routine vaccination?

Official regulatory documents state that the Easy Six Vaccine is indicated for primary and booster vaccination. Its use is determined by and should be in accordance with official national recommendations for routine childhood immunization programs.


Q: When was the Easy Six Vaccine first approved for use?

The vaccine was granted marketing authorization by major regulatory bodies in a phased approach. For example, the European Medicines Agency (EMA) granted authorization in February 2016, and the US Food and Drug Administration (FDA) granted authorization in December 2018.


Q: Where can I find the official prescribing information for Easy Six Vaccine?

Official prescribing information is made available by the government regulatory authorities that approved the vaccine. You can typically find these detailed documents, such as the Summary of Product Characteristics (SmPC) or the Full Prescribing Information, on the websites of bodies like the FDA or EMA.


Q: Is there any aluminum or mercury used in the Easy Six Vaccine formulation?

According to the official ingredient list, the vaccine contains aluminum salts. Aluminum is used as an adjuvant, which is an ingredient that is used to enhance the immune response. Regulatory documents confirm the vaccine does not contain mercury-based preservatives (thimerosal).


Q: Does the Easy Six Vaccine contain egg proteins or gelatin?

Official regulatory documents indicate that the Easy Six Vaccine does not contain gelatin or egg proteins. However, trace amounts of other materials, such as bovine serum albumin or yeast protein, may remain from the manufacturing process.


Q: Has the Easy Six Vaccine been tested on pregnant women?

Regulatory documents state that the vaccine is not intended for administration to women of child-bearing age. Its indicated use is for infants and toddlers, and information regarding its use during pregnancy is therefore not contained in the official prescribing information.


Q: How is the Easy Six Vaccine different from other vaccines with similar names?

Official prescribing information may detail differences from other combination vaccines. For instance, the Easy Six Vaccine is notable for including the Hepatitis B antigen as part of its combination and is supplied as a fully liquid, ready-to-use formulation.


Q: Are there different versions of the Easy Six Vaccine available?

While the Easy Six Vaccine refers to one specific product, other combination vaccines exist that protect against a similar or slightly different number of diseases. These variations depend on the manufacturer and the specific licenses granted in different countries.


Q: What ingredients are listed in the Easy Six Vaccine?

The vaccine contains active components (toxoids and antigens) as well as several inactive ingredients, or excipients. These may include aluminum salts, trace amounts of antibiotics (e.g., neomycin), and remnants of manufacturing materials.


Q: Is it true that the Easy Six Vaccine causes flu-like symptoms?

Official documents list common post-vaccination reactions that may resemble flu-like symptoms. These reactions, which include a fever (38.0 C), irritability, and somnolence (drowsiness), are typically mild and transient.


Q: Is it normal to feel tired the day after receiving the Easy Six Vaccine?

Official adverse reaction documents list somnolence (drowsiness) as a very common reaction. Tiredness is also listed as an uncommon reaction. These are temporary physical responses that are documented in the official prescribing information.


Q: Why do some people feel pain or swelling at the injection site?

Local reactions, such as pain, swelling, and redness at the injection site, are described as Very Common expected local reactions documented in the official prescribing information. These symptoms typically resolve within 48 hours.


Q: If I have allergies to certain food items, can I still take the Easy Six Vaccine?

The vaccine is contraindicated if there is a known allergy to any of its components. Because certain yeast proteins or bovine serum albumin may be present in trace amounts from the manufacturing process, the relevance of any specific food allergy is a factor for a healthcare professional to consider.


Q: If I have a history of mild allergic reactions, is the Easy Six Vaccine still appropriate?

The vaccine is contraindicated (should not be used) if a person has experienced known hypersensitivity or an allergic reaction to any of its components. Guidance regarding a history of mild reactions is not contained in the official documentation, and clarification should be sought from a healthcare professional.


Q: Can individuals with a history of certain chronic health issues receive the Easy Six Vaccine?

Official documentation states that a severe, uncontrolled neurological disorder is a safety restriction. Additionally, the expected immune response may be reduced if the vaccine is given during immunosuppressive therapy. The official documentation advises that the risk and benefit be carefully weighed by a healthcare professional.


Q: Is there any information about using the Easy Six Vaccine in people with autoimmune conditions?

Official information addresses the use of the vaccine in the context of immunosuppressive therapies, which are often used to manage autoimmune conditions. These therapies may reduce the vaccine's expected immune response. This factor is for a healthcare professional to review and discuss.


Q: How long does the protection from the Easy Six Vaccine usually last?

Research explores the persistence of the immune response, with data showing antibody levels persisting following the booster dose up to preschool age. Official studies note that long-term durability of protection beyond the preschool years is not fully established, and follow-up studies are ongoing.


Q: How long did the clinical trials for the Easy Six Vaccine last?

Clinical studies involved monitoring the immune response for the primary series and the subsequent booster dose. The official documentation details follow-up periods that extended to 15 months of age and beyond to assess the persistence of the immune response.


Q: What is the research evidence showing that the Easy Six Vaccine helps prevent the target diseases?

Studies primarily measure immunogenicity, which is the body's ability to produce specific antibodies against the six components. Official data documents that the rates of seroprotection (antibody levels) meet predefined criteria when compared to other approved vaccines.


Q: What does 'clinical efficacy' mean in the studies for the Easy Six Vaccine?

In the vaccine studies, the main outcome measure is often Immunogenicity, which quantifies antibody production. This measure is used as a surrogate endpoint—an indirect marker of protection—rather than relying solely on direct clinical efficacy (prevention of disease) data for all components.


Q: Do studies exist comparing outcomes between vaccinated and unvaccinated groups?

The pivotal clinical studies for the Easy Six Vaccine primarily involved comparisons against licensed comparator vaccines already in use. These studies were designed to confirm that the immune response of the combination vaccine was not inferior to the reference vaccines.


Q: If I received one dose, but missed the second, is the first dose still effective?

The prescribed schedule requires a full primary series of two or three doses followed by a booster dose to establish the complete immune response documented in the studies. The official documentation does not comment on the level of protection attained after a single, incomplete dose.

Advertisements

How should Easy Six Vaccine be stored and disposed of?

The Easy Six Vaccine (DTwP-HepB-Hib-IPV) requires strict adherence to documented cold chain and handling conditions to maintain its effectiveness, as mandated by regulatory documents.

Official Storage Conditions

Condition Requirement
Temperature Store in a refrigerator between 2 C and 8 C (35.6 F to 46.4 F).
Prohibition The vaccine must not be frozen; freezing renders the product inactive.
Protection Keep in the original container/outer carton to shield the contents from light.
Child Safety Store the vaccine out of the sight and reach of children.

Disposal Instructions

Unused product or waste material must be disposed of according to local requirements for pharmaceutical waste. Medicines should not be disposed of via wastewater (e.g., down the sink or toilet) or in regular household trash. Any unused single-dose preparation must be discarded after use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Easy Six Vaccine found in:

A-Z Index: